In contrast, experimental manipulation of ECM with an anti‐LOXL2 antibody in syngeneic orthotopic pancreatic ductal adenocarcinoma (PDA) mouse models resulted in a significant decrease in ECM content, decreased tissue stiffness, and accelerated tumor growth, resulting in decreased overall survival. Here, LOXL2 is linked to neoplasm.